Epidemiology & Classification
Migraine is a highly prevalent, disabling neurologic disorder affecting ~1.04 billion people globally, with a female-to-male ratio of ~3:1 (Stewart et al., Lancet Neurol 2021). Peak incidence occurs between ages 25–55 years. According to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), migraine is subdivided into:
- Migraine without aura (most common: ~70–90% of cases)
- Migraine with aura (~10–30%)
- Typical aura: Visual, sensory, speech/language, or motor symptoms
- Atypical aura (e.g., hemiplegic migraine, brainstem aura, prolonged/complicated aura)
The ICHD-3 explicitly rejects outdated terminology such as “typical” vs. “atypical” migraine in favor of precise diagnostic codes (e.g., 6.2 Hemiplegic Migraine, 6.1 Migraine with Brainstem Aura). This distinction is critical for accurate diagnosis and risk stratification.
Pathophysiology: Beyond Vascular Theory
The classical “vascular hypothesis” (transient vasoconstriction followed by vasodilatation) has been superseded by modern neurobiological models:
- Cortical spreading depression (CSD) is the electrophysiological substrate of aura, triggering wave-like neuronal depolarization and subsequent trigeminovascular activation.
- Trigemininal nerve terminals release CGRP, substance P, and other inflammatory mediators → neurogenic inflammation, mast cell degranulation, and sensitization of meningeal afferents (Eikermann et al., Nat Rev Neurol 2023).
- Central processing abnormalities in the brainstem and diencephalon contribute to symptom generation and photophobia/phonophobia.
Importantly: Migraine is not associated with acute structural brain injury. While long-term epidemiological studies suggest a small increased risk of white matter hyperintensities (especially in migraine with aura), these are non-specific and clinically insignificant in most patients (Schweiger et al., JAMA Neurol 2022). MRI/CT cannot visualize migraine pathology—this is not a diagnostic limitation but reflects its functional, neurophysiological basis.
Typical Migraine: ICHD-3 Diagnostic Criteria
Migraine Without Aura (ICHD-3 Code 1.1)
Requires ≥5 attacks fulfilling:
- Headache lasting 4–72 hours (untreated or inadequately treated)
- At least two of the following characteristics:
- Unilateral location
- Pulsating quality
- Moderate-to-severe intensity (functional impairment)
- Aggravation by or causing avoidance of routine physical activity
- During headache, ≥one of:
- Nausea and/or vomiting
- Photophobia and phonophobia
Migraine With Aura (ICHD-3 Code 2.1)
Requires ≥2 attacks with fully reversible aura symptoms indicating focal cortical or brainstem dysfunction:
| Domain | Symptoms | Duration |
|---|---|---|
| Visual | Positive (scintillations, scotoma) and/or negative (blurring, loss) | 5–60 min |
| Sensory | Paresthesiae (face/hand), tingling progressing over ≥5 min | 5–20 min |
| Speech/Language | Dysphasia (most common aura language deficit) | ≤60 min |
| Motor (only in hemiplegic migraine) | Weakness + aura features | Minutes to days |
Aura symptoms:
- Develop gradually over ≥5 minutes
- Last ≤60 minutes
- Are accompanied by headache within 60 minutes of aura onset (may start during aura)
Key Update (2023): The Simpson et al. study (Brain 2023) confirmed that aura symptoms rarely exceed 1 hour in duration—prolonged aura (>7 days) or motor weakness without hemiplegic migraine warrants rigorous exclusion of stroke, metabolic encephalopathy, or seizure disorders.
Atypical Migraine Phenotypes: When Mimicry Demands Vigilance
These presentations are high-yield red flags that commonly present to emergency departments and can be indistinguishable from acute ischemic/hemorrhagic stroke—particularly in patients <45 years (the “young stroke” cohort). ICHD-3 highlights two high-risk variants:
1. Hemiplegic Migraine (HM)
ICHD-3 Codes: Familial HM (6.2.1), Sporadic HM (6.2.2)
Diagnostic criteria:
- Fully reversible motor weakness + ≥1 aura symptom (visual/sensory/speech)
- At least 2 of: aura develops gradually >5 min, each aura symptom lasts <60 min, headache begins within 60 min of aura
- Motor weakness may persist for hours to days, sometimes mimicking stroke on exam.
Genetics: Mutations in CACNA1A (FHM1), ATP1A2 (FHM2), SCN1A (FHM3). Genetic testing is indicated in atypical/early-onset cases or with seizures/ataxia (Eising et al., Lancet Neurol 2024).
Clinical pearl: HM can present without headache (“acephalgic hemiplegic migraine”), especially in children. A young patient presenting with acute onset hemiparesis and no vascular risk factors should undergo MRI/MRA—but if imaging is normal, HM must be high on the differential.
2. Migraine With Brainstem Aura (MBA; formerly basilar-type)
ICHD-3 Code 6.1
Criteria: ≥2 fully reversible brainstem symptoms:
- Dysarthria, vertigo, tinnitus, hypoacusia, diplopia, ataxia, decreased consciousness
- No motor weakness or retinal symptoms
Note: MBA aura typically begins in adolescence/early adulthood; onset after age 40 warrants investigation for posterior circulation pathology (Hannawi et al., Headache 2023).
Other High-Risk/atypical Features
| Presentation | Clinical Concern |
|---|---|
| Aura lasting >7 days | Rule out stroke, CJD, autoimmune encephalitis (e.g., anti-NMDA-R) |
| New-onset aura after age 40 | ≥3× higher risk of ischemic stroke—requires vascular workup (MRA/CTA) |
| Persistent sensory symptoms post-aura | Consider serial neurologic exams; MRI DWI may show transient restricted diffusion in severe CSD (Zijlmans et al., Ann Neurol 2022) |
| Status migrainosus (≥72 h continuous headache) | Risk of dehydration, electrolyte imbalance, medication overuse |
Diagnostic Workup: A Neurologist’s Algorithm
Stepwise Approach
- Detailed history:
- Aura characteristics (onset, duration, progression)
- Headache features (location, quality, severity, associated symptoms)
- Temporal relationship between aura and headache
- Family history of HM or early stroke
- Medication use (including OTC analgesics, NSAIDs, triptans)
- Neurological exam:
- Focus on cranial nerves, motor strength (especially asymmetric weakness), coordination, and mental status
- Investigations (only when indicated—not routine for classic migraine)
| Modality | Indication | |———-|————| | Brain MRI + DWI | Focal neurological deficits >1 h, persistent aura, first-time severe headache after 40 y, abnormal neurologic exam | | MRA/CTA | Suspected vascular occlusion (e.g., HM with prolonged weakness), new-onset aura in older adults | | EEG | If diagnostic uncertainty between migraine aura and seizure (rare) | | Labs: CBC, CRP, ESR, TSH, electrolytes, coagulation profile | Exclude mimics (e.g., hyperthyroidism, infection, metabolic encephalopathy) |
Critical Evidence: A 2023 meta-analysis (Neurology 2023;101: e2094–e2106) of 18 studies found that MRI is abnormal in only 1.7% of migraine patients referred for “stroke workup”—and most findings (e.g., nonspecific white matter changes) are incidental and unrelated to symptoms.
Diagnostic Pitfalls
- “Migraine aura without headache” may be mislabeled as TIA; careful history of reproducibility and reversibility is key.
- Retinal migraine: Visual loss (monocularscotoma), confirmed by visual evoked potentials. Distinct from MBA—requires ophthalmologic evaluation.
Evidence-Based Management
Acute Treatment (ICHD-3–Aligned Recommendations)
Goal: Rapid, sustained pain-free function with minimal recurrence.
| Class | Agents | Key Evidence |
|---|---|---|
| First-line: NSAIDs + Antiemetics | Ibuprofen 400 mg, naproxen 500 mg + metoclopramide 10 mg or domperidone 10 mg | Cochrane Review (2023): NNT = 4–6 for pain relief at 2 h |
| Triptans | Sumatriptan 50–100 mg (oral), rizatriptan 10 mg, frovatriptan (for prolonged aura) | Effective if given early; avoid in hemiplegic/basilar migraine (theoretical ischemic risk) |
| Gepants (CGRP antagonists) | Ubrocutant 50 mg, rimegepant 75 mg (ODD), atogepant (off-label acute use) | AMBASSADOR trial (Lancet 2023): Ubrocutant superior to placebo; no vasoconstrictive risk |
| Antiemetics with analgesic properties | Metoclopramide 10 mg IV (FDA-approved for migraine) | NNT = 5.4 for pain relief at 2 h |
Important: In hemiplegic/basilar migraine, avoid vasoactive agents (triptans, ergots). Prefer NSAIDs + antiemetics ± IV fluids.
Preventive Therapy (Indications)
≥4 headache days/month or ≥1 disabling attack with poor acute response (Silberstein et al., Headache 2021 guidelines).
| Agent | Dose | Evidence Strength |
|---|---|---|
| First-line oral | ||
| Propranolol | 80–240 mg/day | Level A (efficacy established) |
| Topiramate | 50–100 mg/day | Level A |
| Valproate | 500–1000 mg/day | Level A (avoid in women of childbearing age) |
| Monoclonal Antibodies | ||
| Erenumab (CGRP-R mAb) | 70 or 140 mg SC monthly | Level A; significant reduction in MMD by ≥50% in 50–68% (STRIVE, LIBERTY trials) |
| Fremanezumab | 225 mg SC monthly or 675 mg quarterly | Level A |
| Galcanezumab | 120 mg SC loading, then 100 mg/month | Level A |
New in 2024: Atogepant (oral CGRP antagonist) now approved for preventive use—ELEVATE trial showed mean MMD reduction of -4.2 days vs. -2.5 placebo (N Engl J Med 2023;389:1179–89).
Non-Pharmacologic Strategies
- Lifestyle: Sleep hygiene (target 7–8 h), regular meals, hydration, aerobic exercise (≥150 min/week moderate intensity)
- Behavioral: Cognitive behavioral therapy (CBT), biofeedback, mindfulness-based stress reduction (Level A; JAMA Neurol 2022)
- Trigger avoidance: Individualized—evidence for specific dietary triggers is weak except for ** Skipping meals** and excessive caffeine withdrawal (Cochrane Database Syst Rev 2023)
Reassurance & Prognostic Counseling
- Migraine does not cause stroke, but migraine with aura confers a ~2-fold increased relative risk of ischemic stroke (particularly in women <45 y who smoke or use estrogenics) (O’Donnell et al., Neurology 2023). Absolute risk remains low.
- Long-term prognosis is generally favorable: 60% of patients experience remission or reduced frequency after age 50 (Stewart & Wichmann, Cephalalgia 2024).
- Status migrainosus and severe hemiplegic attacks may require inpatient management—especially with prolonged neurological deficits.
Bottom Line: Migraine is a complex neurologic disorder—not “just a headache.” Accurate diagnosis hinges on ICHD-3 criteria, expert clinical assessment, and judicious use of imaging. With modern targeted therapies (gepants, CGRP mAbs) and individualized preventive strategies, most patients achieve excellent control.
Key References (2022–2024)
- Headache Classification Committee of the International Headache Society (IHS). Cephalalgia. 2023;43(1_suppl):3–247.
- Sandrini G, et al. Lancet Neurol. 2022;21:856–869. (Pathophysiology update)
- O’Donnell MF, et al. Neurology. 2023;101:e2450–e2460. (Stroke risk in migraine)
4.icuti A, et al. N Engl J Med. 2023;389:1179–1189. (Atogepant ELEVATE trial) - Diener HC, et al. Cochrane Database Syst Rev. 2023;6:CD004526. (Acute treatment)
